MaxCyte-Logo-600x600.png
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
12. Oktober 2022 08:00 ET | MaxCyte, Inc
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
28. September 2022 08:05 ET | MaxCyte, Inc
Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for...
MaxCyte-Logo-600x600.png
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
21. September 2022 08:05 ET | MaxCyte, Inc
Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept....
MaxCyte-Logo-600x600.png
MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
07. September 2022 16:05 ET | MaxCyte, Inc
ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
10. August 2022 16:05 ET | MaxCyte, Inc
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte,...
MaxCyte-Logo-600x600.png
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
15. Juli 2022 08:00 ET | MaxCyte, Inc
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
12. Juli 2022 08:00 ET | MaxCyte, Inc
GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13. Mai 2022 16:30 ET | MaxCyte, Inc
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte Reports First Quarter Financial Results
09. Mai 2022 16:05 ET | MaxCyte, Inc
GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte-Logo-600x600.png
MaxCyte to Participate in Upcoming Investor Conferences
03. Mai 2022 16:05 ET | MaxCyte, Inc
GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...